MADRIGAL PHARMACEUTICALS ($MDGL) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of -$3.25 per share, beating estimates of -$4.11 by $0.86. The company also reported revenue of $311,340,000, beating estimates of $308,313,635 by $3,026,365.
You can see Quiver Quantitative's $MDGL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MADRIGAL PHARMACEUTICALS Insider Trading Activity
MADRIGAL PHARMACEUTICALS insiders have traded $MDGL stock on the open market 153 times in the past 6 months. Of those trades, 0 have been purchases and 153 have been sales.
Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:
- PAUL A FRIEDMAN has made 0 purchases and 38 sales selling 49,600 shares for an estimated $26,657,462.
- REBECCA TAUB has made 0 purchases and 42 sales selling 40,676 shares for an estimated $21,675,986.
- KENNETH BATE has made 0 purchases and 11 sales selling 16,575 shares for an estimated $8,027,354.
- RICHARD S LEVY has made 0 purchases and 14 sales selling 8,500 shares for an estimated $4,428,197.
- MARDI DIER (EVP and CFO) has made 0 purchases and 28 sales selling 7,338 shares for an estimated $3,772,798.
- WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 3 sales selling 5,640 shares for an estimated $2,875,678.
- CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 14 sales selling 3,287 shares for an estimated $1,713,308.
- SHANNON T KELLEY (General Counsel) has made 0 purchases and 3 sales selling 1,052 shares for an estimated $499,671.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
MADRIGAL PHARMACEUTICALS Hedge Fund Activity
We have seen 194 institutional investors add shares of MADRIGAL PHARMACEUTICALS stock to their portfolio, and 174 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 257,847 shares (-14.0%) from their portfolio in Q4 2025, for an estimated $150,154,621
- PAULSON & CO. INC. removed 200,001 shares (-10.5%) from their portfolio in Q4 2025, for an estimated $116,468,582
- BANK OF AMERICA CORP /DE/ added 171,733 shares (+70.3%) to their portfolio in Q4 2025, for an estimated $100,006,995
- DEUTSCHE BANK AG\ added 154,767 shares (+414.5%) to their portfolio in Q4 2025, for an estimated $90,127,014
- ARMISTICE CAPITAL, LLC added 145,723 shares (+121.5%) to their portfolio in Q4 2025, for an estimated $84,860,331
- LORD, ABBETT & CO. LLC added 142,653 shares (+139.7%) to their portfolio in Q4 2025, for an estimated $83,072,548
- ALKEON CAPITAL MANAGEMENT LLC added 120,000 shares (+100.0%) to their portfolio in Q4 2025, for an estimated $69,880,800
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
MADRIGAL PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 01/20/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/21/2025
- Oppenheimer issued a "Outperform" rating on 11/20/2025
- Truist Securities issued a "Buy" rating on 11/19/2025
- Canaccord Genuity issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for MADRIGAL PHARMACEUTICALS, check out Quiver Quantitative's $MDGL forecast page.
MADRIGAL PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $MDGL recently. We have seen 9 analysts offer price targets for $MDGL in the last 6 months, with a median target of $650.0.
Here are some recent targets:
- Alexandria Hammond from B of A Securities set a target price of $529.0 on 02/20/2026
- Eliana Merle from Barclays set a target price of $964.0 on 01/28/2026
- Jonathan Wolleben from Citizens set a target price of $745.0 on 01/20/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $900.0 on 12/19/2025
- William Woods from B. Riley Securities set a target price of $670.0 on 12/11/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $620.0 on 11/21/2025
- Jay Olson from Oppenheimer set a target price of $650.0 on 11/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
